GT
MLTX icon

Glenmede Trust’s MoonLake Immunotherapeutics MLTX Stock Holding History

Glenmede Trust’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$261K Buy
+6,690
New +$288K ﹤0.01% 1131

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Glenmede Trust's MLTX Position: Q1 2025 in Review

Glenmede Trust opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2025: 6,690 shares worth $261K. The stake represents ﹤0.01% of the portfolio and ranks #1131 among its holdings.

136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

  • Glenmede Trust held 6,690 shares of MoonLake Immunotherapeutics worth $261K as of Q1 2025.
  • MoonLake Immunotherapeutics was a new Glenmede Trust position in Q1 2025.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2025, its #1131 holding.
  • 136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.